Glycemic and weight changes after persistent use of incident oral diabetes therapy: a veterans administration retrospective cohort study
- 26 September 2010
- journal article
- research article
- Published by Wiley in Pharmacoepidemiology and Drug Safety
- Vol. 19 (11) , 1108-1112
Abstract
Purpose: Systematic reviews have reported that sulfonylureas and metformin were as effective in reducing hemoglobin A1c (A1C) as other oral antidiabetic drugs (OADs) in clinical trial populations. Data on comparative effectiveness of OADs in other populations is limited. The objective was to compare the effectiveness of incident OAD regimens in reducing A1C and to compare the effect of OADs on body mass index (BMI).Methods: Retrospective cohort study using data from the Veterans Affairs Mid‐South network (2001–2007). Of 18 205 veterans who filled 19 511 incident OAD prescriptions, 2096 had complete covariates, persisted on their incident treatment for 12 months, and had baseline and 12‐month A1C values. For the BMI analysis, 2484 patients had complete information. Incident OAD regimens included metformin and sulfonylureas. Primary outcomes were 12‐month A1C and BMI, which were compared controlling for demographic characteristics, baseline A1C and BMI, psychiatric diagnoses, and healthcare utilization.Results: Median [interquartile range (IQR)] A1C decreased from 7.1% [6.5, 7.8] at baseline to 6.5% [6.0, 7.0] at 12 months. Twelve month‐A1C in sulfonylurea users was similar to metformin users. The median [IQR] BMI decreased from 31.1 [27.8, 34.9] to 30.7 [27.5, 34.5] kg/m2. Sulfonylureas were associated with a significantly higher 12‐month BMI than metformin (12‐month adjusted mean difference: 1.05 kg/m2, 95%CI: 0.90–1.20, p < 0.0001).Conclusions: These analyses support the use of metformin as first choice of OAD because of similar glycemic control but improved BMI when compared to sulfonylureas. Copyright © 2010 John Wiley & Sons, Ltd.Keywords
This publication has 11 references indexed in Scilit:
- Effect of Noninsulin Antidiabetic Drugs Added to Metformin Therapy on Glycemic Control, Weight Gain, and Hypoglycemia in Type 2 DiabetesJAMA, 2010
- Glucose Control and Vascular Complications in Veterans with Type 2 DiabetesNew England Journal of Medicine, 2009
- Standards of Medical Care in Diabetes—2009Diabetes Care, 2009
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Effects of Intensive Glucose Lowering in Type 2 DiabetesNew England Journal of Medicine, 2008
- Systematic Review: Comparative Effectiveness and Safety of Oral Medications for Type 2 Diabetes MellitusAnnals of Internal Medicine, 2007
- Veterans’ Access to and Use of Medicare and Veterans Affairs Health CareMedical Care, 2007
- Validity of a Prescription Claims Database to Estimate Medication Adherence in Older PersonsMedical Care, 2006
- Pharmacologic Therapy for Type 2 Diabetes MellitusAnnals of Internal Medicine, 1999
- The Robust Inference for the Cox Proportional Hazards ModelJournal of the American Statistical Association, 1989